I-Mab (IMAB NASDAQ) stock market data APIs
$2.0644
0.25(12.1%)
as of July 10, 2025
Try our APIs with
free plan!
I-Mab Financial Data Overview
Price chart is built with
Anychart
I-Mab, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.
Prev. Close
2.0644
Open
2.3165
High
2.3807
Low
2.0644
52 wk Range
0.595-3.075
Market Cap
167 M
Shares Outstanding
81 660 K
Revenue
3 492 K
EPS
-0.055
Beta
1.166
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get I-Mab data using free add-ons & libraries
Get I-Mab Fundamental Data
I-Mab Fundamental data includes:
- Net Revenue: 3 492 K
- EBITDA: -47 981 500
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-04-03
- EPS/Forecast: -0.06
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
I-Mab News
New
I-Mab Presents Promising Phase 1b Givastomig Combination Data for Gastric Cancers at ESMO GI 2025
I-Mab (NASDAQ:IMAB) is one of the best-performing NASDAQ stocks according to analysts. On July 2, I-Mab announced the presentation of positive Phase 1b combination data for givastomig at the European ...
I-Mab reports 83% response rate for givastomig in gastric cancer study
ROCKVILLE - I-Mab (NASDAQ:IMAB), a clinical-stage biotech company currently valued at $188 million, announced positive Phase 1b data for its bispecific antibody givastomig in combination with nivoluma...
I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025
Data show confirmed ORR of 83% (10/12) at doses selected for ongoing expansion study Median follow-up of 9.0 months as of the updated data cutoff Responses observed in patients with low PD-L1 and/or...
I-Mab's givastomig shows promising results in gastric cancer study
ROCKVILLE, MD - I-Mab (NASDAQ:IMAB), a clinical-stage biotech company whose stock has surged over 200% in the past six months, announced Monday that data from its first-in-human study of givastomig, a...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
